Research programme: RetroMetabolic therapeutics - ARYx

Drug Profile

Research programme: RetroMetabolic therapeutics - ARYx

Alternative Names: ATI-20,000; ATI-24,000

Latest Information Update: 25 Nov 2016

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator ARYx Therapeutics
  • Class
  • Mechanism of Action
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Suspended Gastrointestinal disorders; Metabolic disorders

Most Recent Events

  • 24 Apr 2008 A lead candidate from this programme has entered clinical development
  • 20 Dec 2007 Preclinical trials in Psychotic disorders in USA (unspecified route)
  • 10 Nov 2006 Preclinical trials in Asthma in USA (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top